What is a limitation of PET/CT compared to other imaging techniques?

What is a limitation of PET/CT compared to other imaging techniques?

• A. Lower costs of procedures
• B. Higher resolution of images
• C. False positives from physiological uptake
• D. Limited availability of PET/CT machines

Answer: (C)

PET/CT scans are a powerful imaging modality that combines the functional imaging capability of Positron Emission Tomography (PET) with the anatomical detail provided by Computed Tomography (CT). However, one notable limitation of this hybrid imaging technique is the potential for false positives due to physiological uptake of radiopharmaceuticals. In PET imaging, certain areas of the body may exhibit increased metabolic activity that can be interpreted as a pathological condition, such as cancer. For example, benign conditions like inflammation or infection can lead to increased glucose uptake by cells, which is detected as increased activity on a PET scan. This physiological uptake can sometimes be misinterpreted as malignancy, resulting in false-positive findings. This challenge is significant in clinical practice because it may lead to unnecessary further testing, anxiety for patients, and additional healthcare costs. Understanding this limitation is crucial for clinicians to interpret PET/CT results accurately. The other options, while relevant to imaging techniques in general, do not specifically align with the inherent challenges of PET/CT. Lower costs and higher resolution are not typical limitations; indeed, PET/CT is often more expensive and has certain resolution advantages over standalone scans. Limited availability can be an issue but is more situational and not a

PET/CT scans are a powerful imaging modality that combines the functional imaging capability of Positron Emission Tomography (PET) with the anatomical detail provided by Computed Tomography (CT). However, one notable limitation of this hybrid imaging technique is the potential for false positives due to physiological uptake of radiopharmaceuticals.

In PET imaging, certain areas of the body may exhibit increased metabolic activity that can be interpreted as a pathological condition, such as cancer. For example, benign conditions like inflammation or infection can lead to increased glucose uptake by cells, which is detected as increased activity on a PET scan. This physiological uptake can sometimes be misinterpreted as malignancy, resulting in false-positive findings.

This challenge is significant in clinical practice because it may lead to unnecessary further testing, anxiety for patients, and additional healthcare costs. Understanding this limitation is crucial for clinicians to interpret PET/CT results accurately.

The other options, while relevant to imaging techniques in general, do not specifically align with the inherent challenges of PET/CT. Lower costs and higher resolution are not typical limitations; indeed, PET/CT is often more expensive and has certain resolution advantages over standalone scans. Limited availability can be an issue but is more situational and not a